[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631379":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":23,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":23,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":23,"overallStatus":75,"whyStopped":23,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Citryll BV","INDUSTRY",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"CIT-013 high dose","EXPERIMENTAL",[12],"Drug: CIT-013 high dose",{"label":14,"type":15,"description":14,"interventionNames":16},"Placebo","PLACEBO_COMPARATOR",[17],"Drug: Placebo",[19,24],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","CIT-013",[9],null,{"type":20,"name":14,"description":25,"armGroupLabels":26,"otherNames":23},"placebo",[14],[28],{"name":29,"affiliation":5,"role":30},"Maarten Kraan","STUDY_DIRECTOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},"Leonie M Middelink","CONTACT","+31613328444","lmiddelink@citryll.com",[38],{"facility":39,"status":23,"city":40,"state":23,"zip":23,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"ICON","Groningen","Netherlands","NL",{"type":44,"coordinates":45},"Point",[46,47],6.56667,53.21917,{"lat":47,"lon":46},[50],{"name":51,"role":34,"phone":23,"phoneExt":23,"email":23},"PI ICON PI ICON",{"type":53,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100631379","phase-1-phase-1-trial-to-evaluate-150-mg-subcutaneous-cit-013-100631379",false,"NCT07499908","Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Trial to Evaluate 150 mg Subcutaneous CIT-013 Administration in Healthy Adult Volunteers","Citysky","Inclusion Criteria:\n\nHealthy men or women, 18 to 75 years of age (inclusive) at screening.\n\nExclusion Criteria:\n\nEvidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the trial, or that would pose an unacceptable risk to the participant in the opinion of the Investigator.",true,"ALL","18 Years","75 Years",{"count":67,"type":68},10,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers",[74],"Healthy Adult","NOT_YET_RECRUITING","2026-04-08",{"date":78,"type":79},"2026-04-13","ACTUAL",{"date":81,"type":68},"2026-05-31",{"date":83,"type":68},"2026-10-31",{"name":5,"class":6},1]